ImClone Narrows Focus To VEGFR2 In Breast Cancer Phase III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Pivotal study is expected this year with the compound in gastric tumors as well.
You may also be interested in...
ImClone’s Late-stage Pipeline Includes A Potential Erbitux Competitor
Five new antibodies in cancer clinical trials sweeten takeover pot for BMS.
FLEX Shows Erbitux’s Strength With Survival Benefit In NSCLC
Bristol-Myers Squibb/ImClone/MerckKGaA’s cetuximab significantly prolongs survival in the first-line treatment of NCSLC.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf